SLD 0.42 ▲0.00% MBG 0.21 ▲0.00% FDC 3.93 ▼-0.76% LF1 1.87 ▼-2.12% LGF 2.38 ▲0.86% DN1 98.00 ▼-0.17% WMX 1.58 ▼-2.46% RG8 2.52 ▲0.40% CTS 0.89 ▲2.89% TET 0.42 ▲1.20% MRE 1.68 ▲0.00% BST 0.27 ▲3.85% EFR 0.01 ▲0.00% RIV 1.20 ▼-0.42% KIT 1.80 ▲0.56% EMUCA 0.89 RF1 3.38 ▲0.00% AIX 9.00 ▲0.22% SLD 0.42 ▲0.00% MBG 0.21 ▲0.00% FDC 3.93 ▼-0.76% LF1 1.87 ▼-2.12% LGF 2.38 ▲0.86% DN1 98.00 ▼-0.17% WMX 1.58 ▼-2.46% RG8 2.52 ▲0.40% CTS 0.89 ▲2.89% TET 0.42 ▲1.20% MRE 1.68 ▲0.00% BST 0.27 ▲3.85% EFR 0.01 ▲0.00% RIV 1.20 ▼-0.42% KIT 1.80 ▲0.56% EMUCA 0.89 RF1 3.38 ▲0.00% AIX 9.00 ▲0.22%

IPD ImpediMed Limited

Healthcare · Medical Devices · website · 66 employees
$0.01
52wk 0.00 – 0.06
Overall
47.7
Value
95.4
Growth
63.8
Health
38.7
Quality
0.0
Momentum
22.3
Dividend
—
Price
About ImpediMed Limited

ImpediMed Limited, a medical technology company, engages in the development, manufacture, and sale of bioimpedance spectroscopy (BIS) systems and software services in Australia, Europe, North America, and internationally. The company offers SOZO Digital Health Platform which transforms fluid status and tissue composition into insights with a single scan; L-Dex Analysis for Lymphedema, designed for early lymphedema detection; BodyComp Analysis; Segmental BodyComp Analysis; and HF-Dex Analysis for Heart Failure. It also provides Lymphedema Prevention Program; and BodyComp Analysis for survivorship health. The company specializes in cancer survivorship, heart health management, medical weight management, wellness, and research. ImpediMed Limited was incorporated in 1999 and is headquartered in Carlsbad, California.

Price analytics

Returns

1 day 50.0%
1 week 20.0%
1 month 20.0%
3 months 0.0%
6 months -62.5%
1 year -88.0%
3 years -96.1%

Risk

Volatility (1y ann.) 150.1%
Beta vs ASX 200 1.81
Sharpe (1y) -0.69
VaR 95% (1-day) -16.7%
Max drawdown (1y) -92.3%
Off 1-year high -88.5%

Technicals

RSI(14) 56
vs 50DMA 19.5%
vs 200DMA -53.6%
Trend Death cross
Fundamental trends
Financial statements
Loading…
Scoring breakdown (2 Oct 2026)
Value 95.4
Trailing P/E
—
Forward P/E
100
PEG ratio
—
EV / EBITDA
100
Price / Book
83
Price / Sales
92
Growth 63.8
Revenue growth (1y)
71
Revenue CAGR (3y)
56
EPS growth (1y)
—
EPS CAGR (3y)
—
Financial Health 38.7
Net debt / EBITDA
—
Interest coverage (EBIT/interest)
0
Current ratio
100
Debt / Equity
21
Quality (Profitability & Cash Flow) 0.0
Return on equity
0
Return on assets
0
Operating margin
0
Net margin
0
Cash conversion (OCF / net income)
—
Dividend / Income —
No meaningful dividend — pillar excluded from the overall score.
Momentum 22.3
6-month return vs ASX 200
0
Price vs 200-day average
0
Price vs 50-day average
100
Position in 52-week range
6

Hover a row's info icon for the exact rule. Bounds and weights are configurable in the Django admin (Scoring configuration).

Score history
Key metrics
Market cap
$21.97M
P/E (trailing)
—
P/E (forward)
-3.24
EPS (trailing)
-0.01
Dividend yield
—
Payout ratio
0.0%
Beta
1.07
EV / EBITDA
-1.10
Price / Book
2.00
ROE
-162.4%
Operating margin
-146.2%
Net margin
-170.4%
Total cash
$15.29M
Total debt
$16.60M
Current ratio
3.81
Debt / Equity
1.63
Free cash flow
$-14.24M
Avg volume
6.05M
Latest annual results (FY ending 30 Jun 2026)
  • Revenue$14.61M
  • Gross profit$12.77M
  • Operating income-$22.46M
  • Net income-$24.91M
  • Diluted EPS-0.01
  • Free cash flow-$19.13M
  • Net debt$1.31M
Sector peers (Healthcare)
TickerMkt cap P/EScore
CSL $84.15B — 54.3
RMD $45.86B 21.2 74.4
SIG $29.91B 43.3 55.6
FPH $21.64B 57.5 71.1
PME $16.34B 61.8 69.0
RHC $12.56B 40.0 40.2
SHL $9.12B 15.0 43.0
COH $8.20B 55.5 39.4